My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    AG-1478 (Tyrphostin AG-1478; NSC693255)
    AG-1478 (Tyrphostin AG-1478; NSC693255)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0560
    CAS #: 153436-53-4Purity ≥98%

    Description: AG-1478 (also known as Tyrphostin AG1478; AG-1478; NSC-693255) is a novel, potent and selective EGFR (epidermal growth factor receptor) inhibitor with potential antitumor and antidiabetic activity. It inhibits EGFR with an IC50 of 3 nM in cell-free assays. AG-1478 also reversibly inhibits rat brain Kv1.5 potassium channels with IC50 of 9.8 µM which is independent of protein tyrosine kinase (PTK) activity. AG-1478 shows potent anti-proliferative activity in vitro against leiomyoma and myometrium cell cultures with IC50 values of 5.6 and 5.7 µM, respectively. Previous studies suggest that EGFR antagonism may be effective for the treatment of various diseases such as cancer, angiotensin II-induced cardiac hypertrophy and diabetic cardiomyopathy. Therefore, AG-1478 has the potential to be used as therapeutics for these disorders.

    References: Cancer Res. 1996;56(17):3859-61; Proc Natl Acad Sci U S A. 2003;100(26):15871-6.

    Related CAS #170449-18-0 (HCl)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)315.75
    FormulaC16H14ClN3O2
    CAS No.153436-53-4
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 25 mg/mL (79.2 mM)
    Water: <1 mg/mL
    Ethanol: 13 mg/mL (41.2 mM)
    Solubility (In vivo) 15% Captisol: 30mg/mL
    SynonymsTyrphostin AG-1478; AG1478;Tyrphostin AG 1478; NSC 693255; NSC-693255; NSC693255;  

    Chemical Name: N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine

    InChi Key: GFNNBHLJANVSQV-UHFFFAOYSA-N

    InChi Code: InChI=1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)

    SMILES Code: COC1=CC2=NC=NC(NC3=CC=CC(Cl)=C3)=C2C=C1OC


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: AG-1478 (also known as Tyrphostin AG-1478) is a potent and selective EGFR (epidermal growth factor receptor) inhibitor with IC50 of 3 nM in cell-free assays. It reversibly inhibits rat brain Kv1.5 potassium channels with IC50 of 9.8 µM which is independent of protein tyrosine kinase (PTK) activity. AG-1478 also inhibits the growth of leiomyoma and myometrium cell cultures with IC50 values of 5.6 and 5.7 µM, respectively. Previous studies suggest that EGFR antagonism may be effective for the treatment of various diseases such as cancer, angiotensin II-induced cardiac hypertrophy and diabetic cardiomyopathy. Therefore, AG-1478 has the potential to be used as therapeutics for these disorders. 


    Kinase Assay: AG-1478 is high selective over ErbB2 and PDGFR with IC50 of >100 μM. AG-1478 preferentially inhibits U87MG cells expressing truncated EGFR with IC50 of 8.7 μM, compared to those expressing endogenous wt EGFR or overexpressing exogenous wt EGFR with IC50 of 34.6 μM and 48.4 μM, respectively, and inhibits the DNA synthesis with IC50 of 4.6 μM, 19.67 μM, and 35.2 μM, respectively. AG-1478 also preferentially inhibits the tyrosine kinase activity and autophosphorylation of the ΔEGFR compared to endogenous or overexpressed exogenous wt EGFR. AG-1478 (0.25 μM) abolishes the MAPK activation induced by Ang II, a Ca2+ ionophore as well as EGF but not by a phorbol ester or platelet-derived growth factor-BB in the VSMC. AG-1478 inhibits EGF-induced mitogenesis of the BaF/ERX and LIM1215 cells with IC50 of 0.07 μM and 0.2 μM, respectively. AG1478 is able to inhibit the function of ATP-binding cassette (ABC) transporters such as ABCB1 and ABCG2, with a more pronounced effect on ABCG2.


    Cell Assay: Cells are exposed to different concentrations of AG-1478 for 72 hours in 96-well plates. The effects of AG-1478 on cell growth are examined using an Alamar Blue assay. A 20-μL aliquot of Alamar Blue is added to each well, and its absorbance is determined using a Spectromax Scanning Micro plate Reader. The effects of AG-1478 are expressed as percentage of growth inhibition using untreated cells as the control (0% inhibition). Cellular DNA synthesis is determined using a [3H]thymidine incorporation assay.

    In VivoAdministration of AG-1478 blocks phosphorylation of the EGFR at the tumor site and inhibits the growth of A431 xenografts that overexpress the WT EGFR and glioma xenografts expressing the de2-7 EGFR. Even subtherapeutic doses of AG-1478 significantly enhance the efficacy of cytotoxic drugs, with the combination of AG-1478 and temozolomide displaying synergistic antitumor activity against human glioma xenografts. The combination of AG-1478 and an anti-EGFR antibody (mAb 806) displays additive and in some cases synergistic, antitumor activity against tumor xenografts overexpressing the EGFR. The combination of AG-1478 (0.4 mg) with a single dose of 25 μCi 90Y-CHX-A''-DTPA-hu3S193 results in a significant enhancement of efficacy compared with either agent alone.
    Animal modelFemale BALB/c nu/nu mice inoculated s.c. with A431 or U87MG.Δ2-7 tumor cells
    Formulation & Dosage Dissolved in 100 mM Captisol; 1 mg/kg; i.p. injection
    ReferencesCancer Res. 1996 Sep 1;56(17):3859-61; Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15871-6; Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7080s-7086s.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    AG-1478 (Tyrphostin AG-1478)

    Small molecule EGFR inhibitors attenuate HFD-induced EGFR phosphorylation and myocardial fibrosis in ApoE−/− mouse hearts.  2016 Apr 18;6:24580. 

    AG-1478 (Tyrphostin AG-1478)

    542 or AG1478 suppress HFD-induced inflammation in ApoE−/− mouse hearts.  2016 Apr 18;6:24580. 

    AG-1478 (Tyrphostin AG-1478)

    EGFR inhibitors reverse HFD-induced hypertrophic remodeling, fibrosis and apoptosis in C57BL/6 mouse heart.  2016 Apr 18;6:24580. 

    AG-1478 (Tyrphostin AG-1478)

    EGFR inhibitors attenuate PA-induced inflammation in H9C2 Cells. 2016 Apr 18;6:24580. 

    AG-1478 (Tyrphostin AG-1478)

    EGFR inhibitors reverse PA-induced hypertrophy, fibrosis and apoptosis in H9C2 cells.  2016 Apr 18;6:24580. 



    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?